Clinical Trials Logo

Retinitis Pigmentosa clinical trials

View clinical trials related to Retinitis Pigmentosa.

Filter by:

NCT ID: NCT03510234 Recruiting - Clinical trials for Pigmentary Retinopathy

Self-confidence Study in Patients With Argus II Artificial Retina

Start date: February 23, 2018
Phase:
Study type: Observational

To evaluate whether the use of the Argus II retinal prosthesis improves the confidence and self-esteem of patients with advanced retinopathy pigmentosa

NCT ID: NCT03444961 Recruiting - Clinical trials for Retinitis Pigmentosa

CAREN Argus Rehab (CARE) Study

CARE
Start date: January 30, 2018
Phase: N/A
Study type: Interventional

The goal of the current project is to fill the unmet clinical needs around the objective assessment of visual function and develop outcome-oriented visual rehabilitation approach using the computer assisted rehabilitation environment (CAREN) system for Argus recipients.

NCT ID: NCT03418116 Recruiting - Clinical trials for Retinitis Pigmentosa

Argus II Retinal Prosthesis System - Better Vision RP Study

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

The study is conducted to evaluate the safety and benefit of the Argus II System in a selected patient population with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius.

NCT ID: NCT03406416 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Study of a Suprachoroidal Retinal Prosthesis

Start date: February 13, 2018
Phase: N/A
Study type: Interventional

This study is a proof of principal, to evaluate a safety and efficacy of a prototype suprachoroidal retinal implant.

NCT ID: NCT03381235 Recruiting - Clinical trials for Retinitis Pigmentosa

Exercise and RP (AVAMC and Emory)

Start date: February 23, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to look in humans at the relationship between moderate or little exercise and their potential effects on the retina in patients with Retinitis Pigmentosa (RP).

NCT ID: NCT03374657 Not yet recruiting - Clinical trials for Retinitis Pigmentosa

A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

Start date: May 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

CPK850 is a recombinant adeno-associated virus 8 (AAV8) vector containing the human RLBP1 gene. The purpose of this first-in-human study is to explore the maximum tolerated dose (MTD) of CPK850 as determined by the single ascending dose ranging portion of the study. This study will also evaluate the safety and potential efficacy of CPK850 on improving visual function in patients with decreased visual function from RLBP1 retinitis pigmentosa due to biallelic mutations in the RLBP1 gene.

NCT ID: NCT03368027 Completed - Clinical trials for Stress, Psychological

Effectiveness of a Cognitive-behavioral Program of Coping With Psychological Stress in People With Retinitis Pigmentosa

RCT
Start date: December 1, 2016
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the efficacy of cognitive - behavioral therapy for the control of psychopathological stress and the disease of people with Retinitis Pigmentosa (RP).

NCT ID: NCT03349242 Recruiting - Clinical trials for Retinitis Pigmentosa

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

Start date: December 19, 2017
Phase: N/A
Study type: Observational

The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically and genetically heterogeneous group of disorders in which there is progressive loss of rod and later cone photoreceptor function leading to severe visual impairment. RP usually occurs as an isolated retinal disorder, but it may also be seen in association with systemic abnormalities.

NCT ID: NCT03328130 Recruiting - Clinical trials for Retinitis Pigmentosa

Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene

Start date: November 6, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a Phase I/II, monocentric, open-label, dose-ranging safety and efficacy gene therapy intervention by subretinal administration of AAV2/5-hPDE6B. At least twelve patients 18 years of age or older, within three consecutive cohorts of patients, will be recruited.

NCT ID: NCT03326336 Not yet recruiting - Clinical trials for Non-syndromic Retinitis Pigmentosa

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

PIONEER
Start date: May 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with documented diagnosis of non-syndromic Retinitis Pigmentosa